Everolimus induces Met inactivation by disrupting the FKBP12/Met complex

Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin FKBP12, a prolyl isomerase with different cellul...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2016-06, Vol.7 (26), p.40073-40084
Hauptverfasser:	Raimondo, Lucia, D'Amato, Valentina, Servetto, Alberto, Rosa, Roberta, Marciano, Roberta, Formisano, Luigi, Di Mauro, Concetta, Orsini, Roberta Clara, Cascetta, Priscilla, Ciciola, Paola, De Maio, Ana Paula, Di Renzo, Maria Flavia, Cosconati, Sandro, Bruno, Agostino, Randazzo, Antonio, Napolitano, Filomena, Montuori, Nunzia, Veneziani, Bianca Maria, De Placido, Sabino, Bianco, Roberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Allosteric Site Animals Cell Line, Tumor Drug Resistance, Neoplasm Everolimus - pharmacology Female Gene Expression Regulation, Neoplastic HCT116 Cells Humans Mice Mice, Nude Neoplasm Transplantation Phosphorylation Receptor Protein-Tyrosine Kinases - metabolism Research Paper RNA Interference TOR Serine-Threonine Kinases - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!